Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis - PubMed
5 hours ago
- #Cost-effectiveness analysis
- #MASH treatment
- #Non-alcoholic fatty liver disease
- Comparison of semaglutide and resmetirom for noncirrhotic MASH with moderate to advanced fibrosis.
- Cost-effectiveness analysis of treatments for non-alcoholic fatty liver disease (NAFLD).
- Use of AI (ChatGPT) for language editing and clarity improvement in manuscript preparation.
- Authors declare no competing interests and take full responsibility for the content.
- References highlight NAFLD/NASH as a leading cause of liver transplant and hepatocellular carcinoma.